Corient Private Wealth LLC Makes New $45,000 Investment in Exagen Inc. (NASDAQ:XGN)

Corient Private Wealth LLC bought a new stake in Exagen Inc. (NASDAQ:XGN) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 11,093 shares of the company’s stock, valued at approximately $45,000.

Separately, Palumbo Wealth Management LLC increased its position in Exagen by 13.5% during the fourth quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company’s stock worth $355,000 after buying an additional 10,340 shares in the last quarter. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Exagen Stock Performance

Shares of XGN stock opened at $4.43 on Thursday. The stock has a market capitalization of $79.29 million, a price-to-earnings ratio of -4.71 and a beta of 1.40. Exagen Inc. has a one year low of $1.30 and a one year high of $6.22. The company’s 50-day simple moving average is $3.90 and its 200-day simple moving average is $3.66. The company has a debt-to-equity ratio of 1.54, a quick ratio of 4.05 and a current ratio of 4.05.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. William Blair reissued an “outperform” rating on shares of Exagen in a research note on Wednesday, March 12th. Canaccord Genuity Group lifted their target price on shares of Exagen from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $8.00 price target on shares of Exagen in a report on Monday, January 13th.

Exagen Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).